Transcript Slide 1

Overview of the three-year work programme
(2010–2012)
Rosemary de Sousa, Roland Simon, Paul Griffiths
30th ScC meeting, June 2009
Triennial and annual work plans
• Three-year strategy (2010–2012) will be implemented
through three annual work plans
• 2010–2012 WP still to be formally adopted by the
Management Board – modification possible
• 2010 WP will need to be drafted for approval at the
December MB (after consultation)
Strategic overview
• Coherence and continuity (2010–2012 built on
progress made in 2007–2009)
• Keep pace with the changing nature of the European
drugs problem and emerging information needs
• Guided by: recast regulation, new EU action plan
• Make best use of scarce and limited resources
•
•
•
•
Rationalisation of current work
Refine dissemination strategy
Encourage and support development of exchange platform
Find room for some new developmental areas
• Synergy with national, regional and international
activities
Broader context
• Commitment to annual reporting
• Founding regulation basis for work – recast to regulation in
2007 gave more emphasis to
• new trends
• identification and dissemination of best practice
• polydrug use including combined use of licit and illicit
substances
• Supply information has always been collected but need to scaleup activities
• EU – drug strategy and action plan(s) have become increasingly
important
• EU enlargement and neighbourhood policy remains an
important factor
Challenges of working in a growing family
• Currently reporting
• All EU Member States
• Norway by special arrangement
• Candidate countries – Croatia and Turkey
• The Russian Federation, Ukraine and other countries
have growing interest in EMCDDA work
• The needs of countries and reporting ability varies
considerably
• Quality control and the analysis of data can raise
political as well as scientific issues
The new work programme… moving forward
Overview of this presentation
• EPI (Paul)
• Monitoring drug situation
• Risk assessment and trends
• RES (Roland)
• Monitoring interventions, responses and solutions
• Improving capacity to evaluate policies and interventions
• Disseminate best practice
• Communication (Rosemary)
Strategic framework for monitoring drugs in
Europe
• Organised around 4 pillars with cross-cutting
and developmental issues
• Focused, developmental and long-term vision
• Continue development of key areas
• Increased emphasis on best practice, quality of interventions
and identifying solutions
• Limited number of strategically important new areas
WP schematic
Monitoring responses to
drugs
Best practices, standards
and guidelines
Drug supply and supply reduction
Drug use in prison settings
Drug treatment
Modelling
Monitoring drug situation
Established systems:
consolidate, improve,
implement
New trends and development
Developmental areas:
in-depth analysis,
testing, consensus building
Three-year work programme – main areas
• Monitoring the
drug situation
• New trends and
development
• Monitoring
responses
• Best practices,
standards and
guidelines
Goal
Provide a sound evidence base
for informed policies and action
through developing and
implementing high quality data
collection tools that permit
analysis of the drug situation, its
impact and the tracking of trends
over time
Area 1: Monitoring drug situation – themes
• Tools and process (1.1)
• Continuing improvements to data management procedures
and processes
• Rationalisation of process
• Improvements to data resources
• Key indicators (1.2)
•
•
•
•
Continued development and refinement (TDI, PDU)
Better assessment and support
Broader and improved analytical concepts
More sensitivity to polydrug use, non-opiates and trends
Area 1 – themes (cont.)
• Developmental areas (1.3)
• Supply reduction
• Price purity, labs drug production – seizures, forensic
science, market analysis, reference group
• Prisons
• Analysis (1.4)
•
•
•
•
More emphasis on scientific publications
Modelling and transversal analysis with RES
Joint working and analytical groups (DatLab)
Global perspective
Three-year work programme – main areas
• Monitoring the
drug situation
• New trends and
development
• Monitoring
responses
• Best practices,
standards and
guidelines
Goal
To develop a more responsive
system for monitoring drug use
and the appearance of new
psychoactive substances and
provide increased understanding
of emerging and new trends of
drug use to facilitate early
responses to potential threats
Area 3: New trends and developments – themes
• Risk assessment (3.1)
•
•
•
•
•
Continue to implement
Coherence with broader strategy
Improve database – forensic science links
Collaboration with Europol and EMEA
Review?
• Emerging trends (3.2)
• Rapid response team
• Proactive case study approach
• Trend spotting and new data sources (pilot)
Three-year work programme – main areas
• Monitoring the drug
situation
• New trends and
development
• Monitoring
responses
• Best practices,
standards and
guidelines
Goal
Continue to monitor the
availability, accessibility and
quality of responses to drug
use in Europe through a set
of systematic, well-defined
and analytically relevant
indicators
Area 2: Monitoring interventions
•
Data collection (2.1)
•
•
•
•
•
Continue data collection procedures
Monitor research literature (especially programme effectiveness)
Analyse complementary data collection mechanisms
Keep in contact with scientific/public debate on interventions
(Re-)Define the set up response indicators (2.2)
1.
2.
3.
4.
5.
Drug policy and legal interventions
Prevention and early intervention
Treatment, harm reduction, health and social interventions
Supply reduction interventions
Drug-related cost and expenditure
Area 2: Monitoring interventions (cont.)
•
Methodological development (2.3)
•
•
•
•
•
•
More cross analyses between EPI and RES data sets
Work on the assessment of policy, legal, financial and
organisational models
Develop intervention profiles
Develop quality standards for interventions
Develop economic modelling of drug issues
More sensible monitoring of service provision for high-risk
populations
Three-year work programme – main areas
• Monitoring the drug
situation
• New trends and
development
• Monitoring
responses
• Best practices,
standards and
guidelines
Goal
Support the development of
evidence-based actions,
standards and guidelines for
best practices and develop
analytical tools to facilitate
assessment of the impact and
effectiveness of drug policy
and interventions
Area 4: Best practices, standard and guidelines
•
Monitor and support tools development to assess
drug policy (4.1)
•
•
•
•
Develop tools for assessment
Expand public expenditure conceptually towards costs of
interventions
More analytical focus in ELDD
Conceptually integrating drug policy, law, and public expenditure
Area 4: Best practices, standard and guidelines
(cont.)
•
Support good practice, guidelines and quality
standards (4.2)
•
•
•
•
•
•
Set up expert groups
Define process for standards and guidelines
Provide information on basic texts, standards and guidelines as
required – taking technical requirements into account
Work towards a better understanding of drug markets
Develop partnership with Europol
Integrate expertise and information from related fields
Keeping communication on target
Timeliness
• Shortened production cycles where possible
• Inclusion of more topical information in reporting
Getting the medium right: accessibility
• Web-based products
• Language issues
Active communication: face-to-face
• Visits from policymakers
• Presentations at conferences
Disseminating and valorising outputs
• Extent to which outputs are reaching their target audience
• Discuss increased involvement of national focal points in
dissemination activities
Responding better to differentiated needs (1)
Policymakers
• Multilingual policy summary accompanies all main products
• Continue to address topical issues of policy interest
• Tailored and rapid response to information requests that inform
policy discussion
Scientists and researchers
• Scientific Committee provides improved forum for dialogue with this
target group
• Visibility increased through publishing in scientific journals
• Networking and training activities
• Assistance for secondary analysis of data sets
• Support for publishing scientific articles into languages other than
English
Responding better to differentiated needs (2)
Practitioners
•
•
•
Further develop tools that allow information to be shared on what responses
work (including Best practice portal)
Bring together existing guidelines and standards
Produce ‘evidence papers’ that review scientific literature in key intervention
areas
Citizens
•
•
Awareness-raising products that coincide with specific calendar events
Improve links to national and international sites with a signposting ‘Drug use
in Europe’ web page
Media
•
•
Continue to build sound contacts with journalists and provide media-friendly
information
Work with national focal points to improve dissemination of EMCDDA
results to national media
Questions and discussions